Compare Stocks: ATNM, KRRO, ADCT, and CRBP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.26 -1.2%	$1.14	$0.78 ▼ $4.98	$162.14M	1.84	1.50 million shs	834,637 shs
ATNM Actinium Pharmaceuticals	$1.18 -1.7%	$1.03	$0.74 ▼ $1.74	$37.10M	0.05	146,766 shs	75,356 shs
CRBP Corbus Pharmaceuticals	$6.92 -3.1%	$9.38	$6.32 ▼ $20.56	$133.31M	2.63	1.32 million shs	932,003 shs
KRRO Korro Bio	$9.51 -0.6%	$12.10	$5.20 ▼ $55.89	$140.92M	3.09	196,003 shs	132,362 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	+19.81%	+10.39%	+21.07%	-65.32%
ATNM Actinium Pharmaceuticals	0.00%	-1.64%	+18.81%	+21.21%	-25.47%
CRBP Corbus Pharmaceuticals	0.00%	-4.86%	-34.56%	-20.49%	-41.04%
KRRO Korro Bio	0.00%	-4.49%	-25.87%	-27.45%	-76.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.26 -1.2%	$1.14	$0.78 ▼ $4.98	$162.14M	1.84	1.50 million shs	834,637 shs
ATNM Actinium Pharmaceuticals	$1.18 -1.7%	$1.03	$0.74 ▼ $1.74	$37.10M	0.05	146,766 shs	75,356 shs
CRBP Corbus Pharmaceuticals	$6.92 -3.1%	$9.38	$6.32 ▼ $20.56	$133.31M	2.63	1.32 million shs	932,003 shs
KRRO Korro Bio	$9.51 -0.6%	$12.10	$5.20 ▼ $55.89	$140.92M	3.09	196,003 shs	132,362 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	+19.81%	+10.39%	+21.07%	-65.32%
ATNM Actinium Pharmaceuticals	0.00%	-1.64%	+18.81%	+21.21%	-25.47%
CRBP Corbus Pharmaceuticals	0.00%	-4.86%	-34.56%	-20.49%	-41.04%
KRRO Korro Bio	0.00%	-4.49%	-25.87%	-27.45%	-76.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	298.41% Upside
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	323.73% Upside
CRBP Corbus Pharmaceuticals	2.60	Moderate Buy	$41.00	492.49% Upside
KRRO Korro Bio	2.92	Moderate Buy	$16.71	75.75% Upside

Current Analyst Ratings Breakdown

Latest ATNM, KRRO, ADCT, and CRBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
8/26/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$35.00
8/20/2026	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
8/17/2026	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/13/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
8/7/2026	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$52.00 ➝ $48.00
8/7/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $35.00
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CRBP Corbus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	KRRO Korro Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	1.97	N/A	N/A	($1.50) per share	-0.84
ATNM Actinium Pharmaceuticals	$35.09M	1.06	N/A	N/A	$1.31 per share	0.90
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$8.40 per share	N/A
KRRO Korro Bio	$6.39M	21.92	N/A	N/A	$5.46 per share	1.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
ATNM Actinium Pharmaceuticals	-$48.82M	$0.36	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
CRBP Corbus Pharmaceuticals	-$78.54M	-$6.19	N/A	N/A	N/A	N/A	-87.05%	-74.22%	11/11/2026 (Estimated)
KRRO Korro Bio	-$117.26M	-$10.00	N/A	N/A	N/A	-1,834.48%	-114.26%	-68.57%	11/11/2026 (Estimated)

Latest ATNM, KRRO, ADCT, and CRBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/6/2026	Q2 2026	CRBP Corbus Pharmaceuticals	-$1.26	-$1.81	-$0.55	-$1.81	N/A	N/A
8/6/2026	Q2 2026	KRRO Korro Bio	-$1.34	-$1.07	+$0.27	-$1.07	$0.21 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
CRBP Corbus Pharmaceuticals	N/A	5.71	5.71
KRRO Korro Bio	N/A	9.55	9.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ATNM Actinium Pharmaceuticals	27.50%
CRBP Corbus Pharmaceuticals	64.64%
KRRO Korro Bio	13.18%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
ATNM Actinium Pharmaceuticals	0.60%
CRBP Corbus Pharmaceuticals	3.50%
KRRO Korro Bio	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	191	127.67 million	121.16 million	Optionable
ATNM Actinium Pharmaceuticals	25	31.44 million	29.32 million	Optionable
CRBP Corbus Pharmaceuticals	36	18.67 million	18.02 million	Optionable
KRRO Korro Bio	57	14.73 million	14.02 million	No Data

ATNM, KRRO, ADCT, and CRBP Headlines

Recent News About These Companies

Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Recommendation of "Moderate Buy" by Analysts

September 21, 2026 | americanbankingnews.com

Korro Bio, Inc. (NASDAQ:KRRO) Given Average Rating of "Moderate Buy" by Brokerages

September 21, 2026 | marketbeat.com

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - September 11, 2026

September 14, 2026 | biospace.comB

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 11, 2026 | markets.businessinsider.com

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 11, 2026 | globenewswire.com

Insider Selling: Korro Bio (NASDAQ:KRRO) SVP Sells 7,347 Shares

September 11, 2026 | insidertrades.com

Korro Bio (NASDAQ:KRRO) SVP Oliver Dolan Sells 7,347 Shares of Stock

September 10, 2026 | marketbeat.com

BlackRock Inc. Takes Position in Korro Bio, Inc. $KRRO

September 5, 2026 | marketbeat.com

Korro Bio, Inc. $KRRO Position Reduced by Atlas Venture Life Science Advisors LLC

September 4, 2026 | marketbeat.com

Nantahala Capital Management LLC Takes $8.70 Million Position in Korro Bio, Inc. $KRRO

August 29, 2026 | marketbeat.com

Korro to Participate in Upcoming Investor Conferences

August 27, 2026 | globenewswire.com

Insider Selling: Korro Bio (NASDAQ:KRRO) Director Sells $398,552.00 in Stock

August 22, 2026 | insidertrades.com

Korro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA Editing

August 20, 2026 | tipranks.com

Korro Bio Advances KRRO-121 Into First Human Trial

August 19, 2026 | tipranks.com

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 14, 2026 | globenewswire.com

Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires $19,283.78 in Stock

August 14, 2026 | insidertrades.com

Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Halozyme (HALO) and Resmed (RMD)

August 12, 2026 | theglobeandmail.com

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

August 10, 2026 | zacks.com

Korro Bio (NASDAQ: KRRO) - Share Price and Research

August 8, 2026 | intelligentinvestor.com.auI

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026 | globenewswire.com

Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV)

July 22, 2026 | defenseworld.netD

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, KRRO, ADCT, and CRBP Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.25 -0.02 (-1.18%)

Closing price 03:59 PM Eastern

Extended Trading

$1.26 +0.01 (+0.48%)

As of 08:00 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Actinium Pharmaceuticals NYSE:ATNM

$1.18 -0.02 (-1.67%)

Closing price 04:00 PM Eastern

Extended Trading

$1.21 +0.03 (+2.54%)

As of 07:58 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Corbus Pharmaceuticals NASDAQ:CRBP

$6.92 -0.22 (-3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$7.05 +0.13 (+1.86%)

As of 07:52 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Korro Bio NASDAQ:KRRO

$9.51 -0.06 (-0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$9.51 0.00 (0.00%)

As of 07:42 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, KRRO, ADCT, and CRBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, KRRO, ADCT, and CRBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, KRRO, ADCT, and CRBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, KRRO, ADCT, and CRBP Company Descriptions

ADC Therapeutics NYSE:ADCT

Actinium Pharmaceuticals NYSE:ATNM

Corbus Pharmaceuticals NASDAQ:CRBP

Korro Bio NASDAQ:KRRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, KRRO, ADCT, and CRBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, KRRO, ADCT, and CRBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, KRRO, ADCT, and CRBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, KRRO, ADCT, and CRBP Company Descriptions

ADC Therapeutics NYSE:ADCT

Actinium Pharmaceuticals NYSE:ATNM

Corbus Pharmaceuticals NASDAQ:CRBP

Korro Bio NASDAQ:KRRO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools